Lipanthyl NT 145 mg/Lipanthyl Supra 160 mg/Lipanthyl 67 mg

Fenofibrate

Hypercholesterolemia & hypertriglyceridemia alone or combined (types IIa, IIb, IV dyslipidemias, as well as types III & V dyslipidemias) in patients unresponsive to dietary & other non-drug therapeutic measures, particularly when there is evidence of associated risk eg, HTN & smoking. Secondary hyperlipoproteinemia if hyperlipoproteinemia persists despite effective treatment of the underlying disease (eg, dyslipidemia in DM). Lipanthyl NT 145 mg Reduce the progression of diabetic retinopathy in patients w/ type 2 diabetes & existing diabetic retinopathy.

Adult Lipanthyl NT 145 mg 1 tab/day. Lipanthyl Supra 160 mg 1 tab/day. Lipanthyl 67 mg 3 cap/day. May be titrated up to 4 cap/day. Moderate renal impairment (CrCl 30-60 mL/min) Initially 1 cap once daily.

Lipanthyl NT 145 mg May be taken with or without food: Swallow whole w/ a glass of water. Lipanthyl Supra 160 mg/Lipanthyl 67 mg Should be taken with food: Swallow whole.

Hypersensitivity. Known photoallergy or phototoxic reaction during treatment w/ fibrates or ketoprofen. Hepatic insufficiency (including biliary cirrhosis & unexplained persistent liver function abnormality); known gallbladder disease; severe CKD; chronic or acute pancreatitis w/ the exception of acute pancreatitis due to severe hypertriglyceridemia. Lipanthyl NT 145 mg/Lipanthyl Supra 160 mg Not to be taken in patients allergic to peanut, arachis oil or soya lecithin.

Secondary causes of hyperlipidemia eg, uncontrolled type 2 DM, hypothyroidism, nephrotic syndrome, dysproteinemia, obstructive liver disease, pharmacological treatment, alcoholism. Hyperlipidemic patients taking estrogens or OCs containing estrogen. Monitor transaminase levels every 3 mth during the 1st 12 mth of therapy & thereafter periodically. Discontinue if AST & ALT levels increase to >3 times the ULN range & if symptoms of hepatitis occur (eg, jaundice, pruritus). Pancreatitis. Patients w/ predisposing factors for myopathy &/or rhabdomyolysis. Measure creatinine during the 1st 3 mth after initiation of therapy & thereafter periodically. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Not recommended for use in hepatic impairment. Pregnancy. Not to be used during lactation. Not recommended in ped <18 yr. Lipanthyl NT 145 mg Fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency.

Increased blood homocysteine level. GI signs & symptoms (abdominal pain, nausea, vomiting, diarrhea, flatulence); increased transaminases.

Enhanced effect & may increase risk of bleeding of oral anticoagulants. Severe cases of reversible renal function impairment w/ cyclosporin. Increased risk of serious muscle toxicity w/ HMG-CoA reductase inhibitors or other fibrates. Reversible paradoxical reduction of HDL-C w/ glitazones. Caution when used w/ CYP2C19, CYP2A6 & CYP2C9 metabolized drugs w/ narrow therapeutic index.

Dyslipidaemic Agents

C10AB05 - fenofibrate ; Belongs to the class of fibrates. Used in the treatment of hyperlipidemia.

Rx